

Supplemental Table for:

Cardiac Safety of Paclitaxel plus Trastuzumab and Pertuzumab in Patients with HER2-Positive Metastatic Breast Cancer  
Anthony F. Yu et al.

**Table S1.** Patient Tumor Characteristics and Treatment Outcome. The list of NET primary site, grade of histology, total number of cycles completed, and off treatment reason for all the study participants.

| ID | Primary Site       | Grade of Histology                           | Number of Cycles | Off Treatment Reason   |
|----|--------------------|--|------------------|--|
| 1  | Lung & Bronchus    | Low  | 2                | Disease progression after beginning treatment                |
| 2  | Small Intestine    | Grade unknown, not stated, or not applicable | 4                | Disease progression after beginning treatment                |
| 3  | Small Intestine    | Grade I                                      | 12               | Disease progression after beginning treatment                |
| 4  | Lung & Bronchus    | Well Differentiated                          | 1                | Withdrawal or refusal after beginning treatment <sup>a</sup> |
| 5  | Pancreas           | Well Differentiated                          | 1                | Withdrawal or refusal after beginning treatment <sup>a</sup> |
| 6  | Unknown or Missing | Well Differentiated                          | 2                | Adverse event/Side effects/Complications <sup>b</sup>        |
| 7  | Pancreas           | Low  | 10               | Disease progression after beginning treatment                |
| 8  | Pancreas           | Well Differentiated                          | 15               | Disease progression after beginning treatment                |
| 9  | Pancreas           | Low  | 15               | Started non-protocol therapy <sup>c</sup>                    |
| 10 | Small Intestine    | Low  | 8                | Adverse event/Side effects/Complications                     |
| 11 | Small Intestine    | Grade unknown, not stated, or not applicable | 3                | Adverse event/Side effects/Complications                     |
| 12 | Small Intestine    | Grade unknown, not stated, or not applicable | 19               | Adverse event/Side effects/Complications                     |
| 13 | Rectum             | Well Differentiated                          | 10               | Disease progression after beginning treatment                |
| 14 | Unknown or Missing | Low  | 2                | MD Discretion <sup>d</sup>                                   |
| 15 | Pancreas           | Grade unknown, not stated, or not applicable | 22               | Disease progression after beginning treatment                |

<sup>a</sup>Patients withdrew from the study due to fatigue prior to receiving two cycles of therapy and having a disease evaluation CT scan, considered as “not evaluable”. <sup>b</sup>Patient was hospitalized with extreme fatigue and could not have any more dose modification, then died within 30 days of coming off treatment. The death was considered possibly related to panobinostat treatment and probably related to neuroendocrine cancer. <sup>c</sup>Patient was off treatment to undergo surgical resection of the primary. <sup>d</sup>Patient underwent embolization due to progression of hepatic metastasis that did not meet RECIST for progression.